Whitehawk Therapeutics, Inc.
WHWK
$2.18
-$0.08-3.54%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 33.48% | 14.43% | 21.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 33.48% | 14.43% | 21.03% |
| Cost of Revenue | 32.81% | 251.88% | -32.97% | 10.53% | -14.19% |
| Gross Profit | -299.69% | -534.54% | 72.98% | -7.18% | 45.85% |
| SG&A Expenses | -27.62% | -24.73% | 20.67% | 6.82% | -35.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.67% | 151.57% | -10.06% | 8.94% | -24.45% |
| Operating Income | -81.40% | -251.32% | 22.01% | -6.97% | 39.63% |
| Income Before Tax | -41.45% | -260.80% | 499.23% | -12.32% | 23.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.45% | -260.80% | 499.23% | -12.32% | 23.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.45% | -260.80% | 499.23% | -12.32% | 23.04% |
| EBIT | -81.40% | -251.32% | 22.01% | -6.97% | 39.63% |
| EBITDA | -82.15% | -252.32% | 22.10% | -6.97% | 39.75% |
| EPS Basic | 44.74% | -41.06% | 371.71% | -11.82% | 23.31% |
| Normalized Basic EPS | 30.70% | -41.08% | 46.31% | -11.80% | 39.43% |
| EPS Diluted | 43.97% | -41.04% | 369.12% | -11.82% | 23.31% |
| Normalized Diluted EPS | 30.70% | -41.08% | 46.71% | -11.80% | 39.43% |
| Average Basic Shares Outstanding | 155.92% | 155.77% | 46.92% | 0.45% | 0.35% |
| Average Diluted Shares Outstanding | 155.92% | 155.77% | 48.00% | 0.45% | 0.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |